Dr. Christopher James Diblasio, MD

Dr. Diblasio practices at Cape Coral Surgery Center in Cape Coral, Florida.

Dr. Diblasio's NPI, 1952524274, was assigned on April 11, 2007. Dr. Diblasio graduated from St. George's University School of Medicine in 2002. Dr. Diblasio holds Florida license ME152458.

Dr. Diblasio's primary practice is Cape Coral Surgery Center, at 2721 Del Prado Blvd Suite 100, Cape Coral, FL 33904. The practice phone is (239) 242-8010.

Dr. Diblasio's primary practice is Cape Coral Surgery Center in Cape Coral, Florida. Dr. Diblasio is also affiliated with Cape Coral Hospital. The medical group on file is Advocate Radiation Oncology. Dmand AI also links Dr. Diblasio to 2 more hospitals, 4 medical groups, 3 group practices and clinics and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Diblasio practices, 8 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Diblasio's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Diblasio is board certified in urology by the American Board of Urology. Dmand AI has Dr. Diblasio's licenses on file in 2 states: Florida and New York.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease and pelvic prolapse among the conditions Dr. Diblasio treats.

CMS data shows 3,021 Medicare services from Dr. Diblasio across 17 procedure codes in 2024, for 584 Medicare patients. Medicare paid $177,034 for them.

CMS counts 584 Medicare patients who saw Dr. Diblasio in 2024. The largest group is 75 to 84, with 272 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 2% are also on Medicaid. Their average risk score is 1.30, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Diblasio's median patient age at 75, with 19% women.

In 2024, Dr. Diblasio wrote 1,802 Medicare Part D claims for 535 patients. 90% of them were for generic drugs. CMS names the drug for 1,700 of them, across 27 drugs with 11 or more claims each, at $485,375 in total drug cost. In 2023, CMS named 1,372 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Diblasio for performance year 2024, reported individually. Dr. Diblasio accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Diblasio as offering telehealth. CMS counts 14 procedures of prostate resection by Dr. Diblasio, more than 69% of the clinicians it reports for that procedure.

Dmand AI links 26 papers to Dr. Diblasio, published from 2007 to 2014. 2008 was the busiest year, with 2. The most frequent topics are Prostatic Neoplasms, Disease Progression and Prostatectomy. Dr. Diblasio has published most often in BJU Int. Dr. Diblasio's most frequent co-authors are Ithaar Derweesh, MD, James A. Eastham, MD and Fernando J. Bianco, MD.

CMS Open Payments shows 251 general payments to Dr. Diblasio from 41 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 81% of the total. Boston Scientific Corporation paid the most, $79,706.

Dmand AI lists 14 awards for Dr. Diblasio, most recently CMS Stage 1 EHR in 2013.

Dr. Diblasio graduated from St. George's University School of Medicine in 2002. Dr. Diblasio is a member of AOA and AUA.

Dr. Diblasio is in network with 19 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.